Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Colomer-Carbonell, Ariadna, Sanabria-Mazo, Juan P., Hernández-Negrín, Halbert, Borràs, Xavier, Suso-Ribera, Carlos, Garciá-Palacios, Azucena, Muchart, Jordi, Munuera, Josep, D'Amico, Francesco, Maes, Michael, Younger, Jarred W., Feliu-Soler, Albert, Rozadilla-Sacanell, Antoni and Luciano, Juan V. (2022) Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open, 12 (1). ISSN 2044-6055

Text (e055351.full) - Published Version Available under License Creative Commons Attribution Non-commercial. Download (496kB)

• Author

Abstract

Introduction There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility and neurobiological effects of LDN for reducing pain in patients with FMS, with a 1-year follow-up. Methods and analysis A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (eg, pain intensity, fatigue and sleep disturbance), and side effects via ecological momentary assessment through the Pain Monitor app during the first 3 months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with MRI at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitisation. Inflammatory biomarkers in serum will also be measured. Ethics and dissemination This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and community engagement activities. Trial registration number NCT04739995.

Item Type:	Article
Official URL:	https://bmjopen.bmj.com/
Additional Information:	© 2021 The Authors
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RA Public aspects of medicine
Date Deposited:	27 Jan 2022 12:45
Last Modified:	16 Nov 2024 08:03
URI:	http://eprints.lse.ac.uk/id/eprint/113563

Actions (login required)

View Item